Protagenic Therapeutics restructures, cuts ~$8M annual costs; CEO and COO terminated

Protagenic Therapeutics, Inc.new

Board approved restructuring to virtual model, focusing on PT00114 Phase 2 trial expected to complete in 9–12 months.
Annual operating expenses to be reduced by ~$8 million when fully implemented; one-time charges not yet estimable.
CEO Barrett Evans and COO Colin Stott terminated effective immediately; both remain on the Board.
All preclinical programs (PHYX-001 through PHYX-005) paused; company pursuing partnerships or out-licensing.
Fiscal year-end changed from Dec 31 to Mar 31; transition report on Form 10-QT for Apr 1–Jun 30, 2025.

item 2.05 item 5.02 item 5.03 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Protagenic Therapeutics, Inc.new: Fiscal year-end changed from December 31 to March 31.

Change: fiscal year change

Exact text from the filing

the Board approved a change in the Company’s fiscal year-end from December 31 to March 31, effective immediately.

View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

Protagenic Therapeutics, Inc.new filing history →

Source: SEC EDGAR

accession 0001641172-25-023588

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.